From Discovery to Delivery: Successful Systems Integration

Patrons want library collections to be unrestricted in scope. Demands for information resources are increasing while libraries are facing decreasing budgets and minimal staffing support. ILL and consortial services can help libraries expand access to collections. Patron-initiated borrowing systems are a current trend in libraries, but seamlessly integrating them is challenging. Our poster will analyze problems in patron-initiated consortial borrowing and lending services. We will introduce our new generation service, which combines more than four complex library systems and allows them to work together in real-time availability: the OPAC, a consortial borrowing system, an ILL system, an ILS, and an authentication system. This service has seamlessly integrated our new discovery tool, WorldCat Local, with our borrowing and lending systems: local, consortial and worldwide ILL. Our patron requests have dramatically increased as requests are now automatically transferred from system to system based on the item’s availability, maintaining rapid delivery. This technological advancement provides more services to our patrons, costs less and improves the time management of our staff

Pirfenidone treatment of idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a discrete clinicopathologic entity defined by the presence of usual interstitial pneumonia on high-resolution CT scan and/or open lung biopsy and the absence of an alternate diagnosis or exposure explaining these findings. There are currently no FDA-approved therapies available to treat this disease, and the 5-year mortality is ∼80%. The pyridone derivative pirfenidone has been studied extensively as a possible therapeutic agent for use in this deadly disease. This review will present the unique clinical features and management issues encountered by physicians caring for IPF patients, including the poor response to conventional therapy. The biochemistry and preclinical efficacy of pirfenidone will be discussed along with a comprehensive review of the clinical efficacy, safety, and side effects and patient-centered foci such as quality of life and tolerability. It is hoped that this information will lend insight into the complex issues surrounding the use of pirfenidone in IPF and lead to further investigation of this agent as a possible therapy in this devastating disease

Chinese Classical Formula Sijunzi Decoction and Chronic Atrophic Gastritis: Evidence for Treatment Approach?

Objective. This aim is to evaluate the effect of Sijunzi decoction (SJZD) treating chronic atrophic gastritis (CAG). Methods. We performed searches in seven databases. The randomized controlled trials (RCTs) comparing SJZD with standard medical care or inactive intervention for CAG were enrolled. Combined therapy of SJZD plus conventional therapies compared with conventional therapies alone was also retrieved. The primary outcome included the incidence of gastric cancer and the improvement of atrophy, intestinal metaplasia, and dysplasia based on the gastroscopy and pathology. The secondary outcomes were Helicobacter pylori clearance rate, quality of life, and adverse event/adverse drug reaction. Results. Six RCTs met the inclusion criteria. The research quality was low in the trials. For the overall effect rate, pooled analysis from 4 trials showed that modified SJZD plus conventional medications exhibited a significant improvement (OR = 4.86; 95% CI: 2.80 to 8.44; P < 0.00001) and without significant heterogeneity compared with the conventional medications alone. None reported the adverse effect. Conclusions. Modified SJZD combined with conventional western medicines appears to have benefits for CAG. Due to the limited number and methodological flaw, the beneficial and harmful effects of SJZD for CAG could not be identified. More high-quality clinical trials are needed to confirm the results